Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

In an editorial, J. Mocco, MD, of Mount Sinai Health System in New York City, characterized the DISTAL and ESCAPE-MeVO ...

Novartis AG agreed to buy US biotech Anthos Therapeutics for as much as $3.1 billion to gain a preventative stroke medicine that could be the first of its kind.

Anthos was founded by Blackstone Life Sciences and Novartis in 2019 to develop, manufacture, and commercialize abelacimab, a ...

Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots.

The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...

With the stroke of a pen, U.S. President Donald Trump last week put a freeze on projects that have helped Ukraine become ...

Novartis (NVS) on Tuesday agreed to acquire biopharmaceutical firm Anthos Therapeutics in a deal worth up to $3.1 billion, as the Swiss pharmaceutical giant looks to boost its cardiovascular portfolio ...

Use of endovascular thrombectomy in patients with acute ischemic stroke caused by occlusions in distal vessels has failed to ...

The acting chair of the, Mark Uyeda, took the first step Tuesday to rolling back a rule that would require thousands of ...

Copyright © 2025 Bleacher Report, Inc. A Warner Bros. Discovery Company. All Rights Reserved.